Biblio

Export 210 results:
Author Title Type [ Year(Desc)]
Filters: Keyword is Amyloid beta-Peptides  [Clear All Filters]
2010
J. C. Morris, Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., and Mintun, M. A., “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
G. He, Luo, W., Li, P., Remmers, C., Netzer, W. J., Hendrick, J., Bettayeb, K., Flajolet, M., Gorelick, F., Wennogle, L. P., and Greengard, P., “Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.”, Nature, vol. 467, no. 7311, pp. 95-8, 2010.
D. A. Gimbel, Nygaard, H. B., Coffey, E. E., Gunther, E. C., Laurén, J., Gimbel, Z. A., and Strittmatter, S. M., “Memory impairment in transgenic Alzheimer mice requires cellular prion protein.”, J Neurosci, vol. 30, no. 18, pp. 6367-74, 2010.
2011
T. E. Golde, Schneider, L. S., and Koo, E. H., “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
C. R. Jack, Vemuri, P., Wiste, H. J., Weigand, S. D., Aisen, P. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Petersen, R. C., Weiner, M. W., and Knopman, D. S., “Evidence for ordering of Alzheimer disease biomarkers.”, Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.
J. M. Castellano, Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., Goate, A. M., Bales, K. R., Paul, S. M., Bateman, R. J., and Holtzman, D. M., “Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.”, Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
A. W. Bero, Yan, P., Roh, J. Hoon, Cirrito, J. R., Stewart, F. R., Raichle, M. E., Lee, J. - M., and Holtzman, D. M., “Neuronal activity regulates the regional vulnerability to amyloid-β deposition.”, Nat Neurosci, vol. 14, no. 6, pp. 750-6, 2011.
M. Jucker and Walker, L. C., “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.”, Ann Neurol, vol. 70, no. 4, pp. 532-40, 2011.
M. Jin, Shepardson, N., Yang, T., Chen, G., Walsh, D., and Selkoe, D. J., “Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.”, Proc Natl Acad Sci U S A, vol. 108, no. 14, pp. 5819-24, 2011.
H. Braak, Thal, D. R., Ghebremedhin, E., and Del Tredici, K., “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
2012
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
J. Gräff, Rei, D., Guan, J. - S., Wang, W. - Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., Su, S. C., Samiei, A., Joseph, N., Haggarty, S. J., Delalle, I., and Tsai, L. - H., “An epigenetic blockade of cognitive functions in the neurodegenerating brain.”, Nature, vol. 483, no. 7388, pp. 222-6, 2012.
D. Head, Bugg, J. M., Goate, A. M., Fagan, A. M., Mintun, M. A., Benzinger, T., Holtzman, D. M., and Morris, J. C., “Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.”, Arch Neurol, vol. 69, no. 5, pp. 636-43, 2012.
J. J. Iliff, Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., G Vates, E., Deane, R., Goldman, S. A., Nagelhus, E. A., and Nedergaard, M., “A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β.”, Sci Transl Med, vol. 4, no. 147, p. 147ra111, 2012.
2013
A. Griciuc, Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. Hoon, Hyman, B. T., and Tanzi, R. E., “Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.”, Neuron, vol. 78, no. 4, pp. 631-43, 2013.
F. Piazza, Greenberg, S. M., Savoiardo, M., Gardinetti, M., Chiapparini, L., Raicher, I., Nitrini, R., Sakaguchi, H., Brioschi, M., Billo, G., Colombo, A., Lanzani, F., Piscosquito, G., Carriero, M. Rita, Giaccone, G., Tagliavini, F., Ferrarese, C., and DiFrancesco, J. C., “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
T. Kondo, Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., Takahashi, K., Asaka, I., Aoi, T., Watanabe, A., Watanabe, K., Kadoya, C., Nakano, R., Watanabe, D., Maruyama, K., Hori, O., Hibino, S., Choshi, T., Nakahata, T., Hioki, H., Kaneko, T., Naitoh, M., Yoshikawa, K., Yamawaki, S., Suzuki, S., Hata, R., Ueno, S. - I., Seki, T., Kobayashi, K., Toda, T., Murakami, K., Irie, K., Klein, W. L., Mori, H., Asada, T., Takahashi, R., Iwata, N., Yamanaka, S., and Inoue, H., “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
C. R. Jack, Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Pankratz, V. S., Donohue, M. C., and Trojanowski, J. Q., “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
2014
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
T. Lu, Aron, L., Zullo, J., Pan, Y., Kim, H., Chen, Y., Yang, T. - H., Kim, H. - M., Drake, D., X Liu, S., Bennett, D. A., Colaiácovo, M. P., and Yankner, B. A., “REST and stress resistance in ageing and Alzheimer's disease.”, Nature, vol. 507, no. 7493, pp. 448-54, 2014.
S. Hoon Choi, Kim, Y. Hye, Hebisch, M., Sliwinski, C., Lee, S., D'Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., Klee, J. B., Zhang, C., Wainger, B. J., Peitz, M., Kovacs, D. M., Woolf, C. J., Wagner, S. L., Tanzi, R. E., and Kim, D. Yeon, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
2016
H. Li, Zhu, H., Wallack, M., Mwamburi, M., Abdul-Hay, S. O., Leissring, M. A., and Qiu, W. Qiao, “Age and its association with low insulin and high amyloid-β peptides in blood.”, J Alzheimers Dis, vol. 49, no. 1, pp. 129-37, 2016.
T. Minh Do, Dodacki, A., Alata, W., Calon, F., Nicolic, S., Scherrmann, J. - M., Farinotti, R., and Bourasset, F., “Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).”, J Alzheimers Dis, vol. 49, no. 2, pp. 287-300, 2016.
S. Yamashita, Kiko, T., Fujiwara, H., Hashimoto, M., Nakagawa, K., Kinoshita, M., Furukawa, K., Arai, H., and Miyazawa, T., “Alterations in the Levels of Amyloid-β, Phospholipid Hydroperoxide, and Plasmalogen in the Blood of Patients with Alzheimer's Disease: Possible Interactions between Amyloid-β and These Lipids.”, J Alzheimers Dis, vol. 50, no. 2, pp. 527-37, 2016.

Pages